Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study

Journal of Viral Hepatitis

Volumn 24, Issue 10, 2017, Pages 850-857

  Boglione, L ^a   Mornese Pinna, S ^a   De Nicolo A ^a   Cusato, J ^a   Cariti, G ^a   Di Perri, G ^a   D'Avolio, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

DAAs; fibrosis; HCV; PEG IFN; PWID

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; BUPRENORPHINE; DACLATASVIR; DASABUVIR; LEDIPASVIR; METHADONE; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ADULT; ADVERSE OUTCOME; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISCELLANEOUS NAMED GROUPS; MODEL FOR END STAGE LIVER DISEASE SCORE; OPIATE SUBSTITUTION TREATMENT; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; AGED; COMBINATION DRUG THERAPY; COMORBIDITY; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG USE; ELASTOGRAPHY; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER CIRRHOSIS; ODDS RATIO; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; DRUG USERS; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85018922173     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12711     Document Type: Article

References (21)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562.
2. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-583.
3. Kim C, Kerr T, Li K, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009;9:270.
4. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58:1215-1224.
5. Grebely J, Raffa JD, Lai C, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18:32-41.
6. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:1050-1057.
7. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009;16:352-358.
8. Papadopoulos V, Gogou A, Mylopoulou T, Mimidis K. Should active injecting drug users receive treatment for chronic hepatitis C? Arq Gastroenterol. 2010;47:238-241.
9. Hepatol J. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236.
10. WHO. Section VIII: WHO toxicity grading scale for determining the severity of adverse events. WHO handbook for Reporting Results of Cancer Treatment. 2003.
11. AIFA IAoD. Registri Farmaci sottoposti a monitoraggio. 2016.
12. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012;31:918-924.
13. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49:561-573.
14. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2013;56:806-816.
15. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80-S89.
16. Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747-752.
17. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(Suppl 2):S105-S110.
18. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19:829-835.
19. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(Suppl 1):69-78.
20. Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of Simeprevir Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37:534-541.
21. de Vos AS, Prins M, Kretzschmar ME. Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? Addiction. 2015;110:975-983.